<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2403257153
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARXIA 120MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Etoricoxib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Arxia contains the active substance etoricoxib. Arxia is one of a group of medicines called<br />selective COX-2 inhibitors. These belong to a family of medicines called non-steroidal antiinflammatory<br />drugs (NSAIDs).<br />What is Arxia used for?<br />Arxia helps to reduce the pain and swelling (inflammation) in the joints and muscles of<br />people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis<br />and gout.</p><p>Arxia is also used for the short term treatment of moderate pain after dental surgery in<br />people 16 years of age and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Arxia:<br /> if you are allergic (hypersensitive) to etoricoxib or any of the other ingredients of this medicine<br />(listed in section 6)<br /> if you are allergic to non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and<br />COX-2 inhibitors (see Possible Side Effects, section 4)<br /> if you have a current stomach ulcer or bleeding in your stomach or intestines<br /> if you have serious liver disease<br /> if you have serious kidney disease<br /> if you are or could be pregnant or are breast-feeding (see &lsquo;Pregnancy, breast feeding, and<br />fertility&rsquo;)<br /> if you are under 16 years of age<br /> if you have inflammatory bowel disease, such as Crohn&rsquo;s Disease, Ulcerative Colitis, or Colitis<br /> if you have high blood pressure that has not been controlled by treatment (check with your<br />doctor or nurse if you are not sure whether your blood pressure is adequately controlled)<br /> if your doctor has diagnosed heart problems including heart failure (moderate or severe types),<br />angina (chest pain)<br /> if you have had a heart attack, bypass surgery, peripheral arterial disease (poor circulation in legs<br />or feet due to narrow or blocked arteries)<br /> if you have had any kind of stroke (including mini-stroke, transient ischaemic attack or TIA).<br />Etoricoxib may slightly increase your risk of heart attack and stroke and this is why it should not<br />be used in those who have already had heart problems or stroke.<br />If you think any of these are relevant to you, do not take the tablets until you have consulted your<br />doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Arxia if:<br /> You have a history of stomach bleeding or ulcers.<br /> You are dehydrated, for example by a prolonged bout of vomiting or diarrhoea.<br /> You have swelling due to fluid retention.<br /> You have a history of heart failure, or any other form of heart disease.<br /> You have a history of high blood pressure. Etoricoxib can increase blood pressure in some<br />people, especially in high doses, and your doctor will want to check your blood pressure from<br />time to time.<br /> You have any history of liver or kidney disease.<br /> You are being treated for an infection. Etoricoxib can mask or hide a fever, which is a sign of<br />infection.<br /> You have diabetes, high cholesterol, or are a smoker. These can increase your risk of heart<br />disease.<br /> You are a woman trying to become pregnant.<br /> You are over 65 years of age.<br />If you are not sure if any of the above apply to you, talk to your doctor before taking Arxia to see if<br />this medicine is suitable for you.<br />Etoricoxib works equally well in older and younger adult patients. If you are over 65 years of age,<br />your doctor will want to appropriately keep a check on you. No dosage adjustment is necessary for<br />patients over 65 years of age.<br />Children and adolescents<br />Do not give this medicine to children and adolescents under 16 years of age.<br />Other medicines and Arxia<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines, including medicines obtained without a prescription.<br />In particular if you are taking any of the following medicines, your doctor may want to monitor you to<br />check that your medicines are working properly, once you start taking Arxia:<br /> medicines that thin your blood (anticoagulants), such as warfarin<br /> rifampicin (an antibiotic)<br /> methotrexate (a drug used for suppressing the immune system, and often used in rheumatoid<br />arthritis)<br /> ciclosporin or tacrolimus (drugs used for suppressing the immune system)<br /> lithium (a medicine used to treat some types of depression)<br /> medicines used to help control high blood pressure and heart failure called ACE inhibitors and<br />angiotensin receptor blockers, examples include enalapril and ramipril, and losartan and<br />valsartan<br /> diuretics (water tablets)<br /> digoxin (a medicine for heart failure and irregular heart rhythm)<br /> minoxidil (a drug used to treat high blood pressure)<br /> salbutamol tablets or oral solution (a medicine for asthma)<br /> birth control pills (the combination may increase your risk of side effects)<br /> hormone replacement therapy (the combination may increase your risk of side effects)<br /> aspirin, the risk of stomach ulcers is greater if you take etoricoxib with aspirin.<br />- aspirin for prevention of heart attacks or stroke:<br />Etoricoxib can be taken with low-dose aspirin. If you are currently taking low-dose aspirin to<br />prevent heart attacks or stroke, you should not stop taking aspirin until you talk to your doctor<br />- aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs):<br />do not take high dose aspirin or other anti-inflammatory medicines while taking etoricoxib.<br />Arxia with food and drink<br />The onset of the effect of Arxia may be faster when taken without food.<br />Pregnancy, breast-feeding, and fertility<br />Pregnancy<br />Arxia tablets must not be taken during pregnancy. If you are pregnant or think you could be<br />pregnant, or if you are planning to become pregnant, do not take the tablets. If you become pregnant,<br />stop taking the tablets and consult your doctor. Consult your doctor if you are unsure or need more<br />advice.<br />Breast-feeding<br />It is not known if Arxia is excreted in human milk. If you are breast-feeding, or planning to<br />breast-feed, consult your doctor before taking Arxia. If you are using Arxia, you must not breast-feed.<br />Fertility<br />Arxia is not recommended in women attempting to become pregnant.<br />Driving and using machines<br />Dizziness and sleepiness have been reported in some patients taking etoricoxib. Do<br />not drive if you experience dizziness or sleepiness.<br />Do not use any tools or machines if you experience dizziness or sleepiness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or<br />pharmacist if you are not sure.<br />Do not take more than the recommended dose for your condition. Your doctor will want to discuss<br />your treatment from time to time. It is important that you use the lowest dose that controls your pain<br />and you should not take Arxia for longer than necessary. This is because the risk of heart attacks<br />and strokes might increase after prolonged treatment, especially with high doses.<br />There are different strengths available for this medicinal product and depending on your disease your<br />doctor will prescribe the tablet strength that is appropriate for you.<br />The recommended dose is:<br />Osteoarthritis<br />The recommended dose is 30 mg once a day, increase to a maximum of 60 mg once a day if needed.<br />Rheumatoid arthritis<br />The recommended dose is 60 mg once a day, increased to a maximum of 90 mg once a day if needed.<br />Ankylosing spondylitis<br />The recommended dose is 60 mg once a day, increased to a maximum of 90 mg once a day if needed.<br />Acute pain conditions<br />Etoricoxib should be used only for the acute painful period.<br />Gout<br />The recommended dose is 120 mg once a day which should only be used for the acute painful period,<br />limited to a maximum of 8 days treatment.<br />Postoperative dental surgery pain<br />The recommended dose is 90 mg once daily, limited to a maximum of 3 days treatment.<br />People with liver problems<br /> If you have mild liver disease, you should not take more than 60 mg a day.<br /> If you have moderate liver disease, you should not take more than 30 mg a day.<br />Use in children and adolescents<br />Arxia tablets should not be taken by children or adolescents under 16 years of age.<br />Elderly<br />No dose adjustment is necessary for elderly patients. As with other medicines, caution should be<br />exercised in elderly patients.<br />Method of administration<br />Arxia is for oral use. Take the tablets once a day. Arxia can be taken with or without food.<br />If you take more Arxia than you should<br />You should never take more tablets than the doctor recommends. If you do take too many Arxia tablets,<br />you should seek medical attention immediately.<br />If you forget to take Arxia<br />It is important to take Arxia as your doctor has prescribed. If you miss a dose, just resume your usual<br />schedule the following day. Do not take a double dose to make up for the forgotten tablet.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you develop any of these signs you should stop Arxia and talk to your doctor immediately (see<br />What you need to know before you take Arxia section 2):<br /> shortness of breath, chest pains, or ankle swelling appear or if they get worse<br /> yellowing of the skin and eyes (jaundice) &ndash; these are signs of liver problems<br /> severe or continual stomach pain or your stools become black<br /> an allergic reaction- which can include skin problems such as ulcers or blistering, or swelling of<br />the face, lips, tongue, or throat which may cause difficulty in breathing<br />The frequency of possible side effects listed below is defined using the following convention: Very<br />common (affects more than 1 user in 10)<br />Common (affects 1 to 10 users in 100)<br />Uncommon (affects 1 to 10 users in 1,000)<br />Rare (affects 1 to 10 users in 10,000)<br />Very rare (affects less than 1 user in 10,000)<br />The following side effects can occur during treatment with Arxia:<br />Very Common:<br /> stomach pain<br />Common:<br /> dry socket (inflammation and pain after a tooth extraction)<br /> swelling of the legs and/or feet due to fluid retention (oedema)<br /> dizziness, headache<br /> palpitations (fast or irregular heartbeat), irregular heart rhythm (arrhythmia)<br /> increased blood pressure<br /> wheezing or shortness of breath (bronchospasms)<br /> constipation, wind (excessive gas), gastritis (inflammation of the lining of the stomach),<br />heartburn, diarrhoea, indigestion (dyspepsia)/stomach discomfort, nausea, being sick (vomiting),<br />inflammation of the oesophagus, mouth ulcers<br /> changes in blood tests related to your liver<br /> bruising<br /> weakness and fatigue, flu-like illness<br />Uncommon:<br /> gastroenteritis (inflammation of the gastrointestinal tract that involves both the stomach and small<br />intestine/stomach flu), upper respiratory infection, urinary tract infection<br /> changes in laboratory values (decreased number of red blood cells, decreased number of white<br />blood cells, platelets decreased)<br /> hypersensitivity (an allergic reaction including hives which may be serious enough to require<br />immediate medical attention)<br /> appetite increases or decreases, weight gain<br /> anxiety, depression, decreases in mental sharpness; seeing, feeling or hearing things that are not<br />there (hallucinations)<br /> taste alteration, inability to sleep, numbness or tingling, sleepiness<br /> blurred vision, eye irritation and redness<br /> ringing in the ears, vertigo (sensation of spinning while remaining still)<br /> abnormal heart rhythm (atrial fibrillation), fast heart rate, heart failure, feeling of tightness,<br />pressure or heaviness in the chest (angina pectoris), heart attack<br /> flushing, stroke, mini-stroke (transient ischaemic attack), severe increase in blood pressure,<br />inflammation of the blood vessels<br /> cough, breathlessness, nose bleed<br /> stomach or bowel bloating, changes in your bowel habits, dry mouth, stomach ulcer,<br />inflammation of the stomach lining that can become serious and may lead to bleeding, irritable<br />bowel syndrome, inflammation of the pancreas<br /> swelling of the face, skin rash or itchy skin, redness of the skin<br /> muscle cramp/spasm, muscle pain/stiffness<br /> high levels of potassium in your blood, changes in blood or urine tests relating to your kidney,<br />serious kidney problems<br /> chest pain<br />Rare:<br /> angioedema (an allergic reaction with swelling of the face, lips, tongue and/or throat which may<br />cause difficulty in breathing or swallowing, which may be serious enough to require immediate<br />medical attention)/anaphylactic/anaphylactoid reactions including shock (a serious allergic<br />reaction that requires immediate medical attention)<br /> confusion, restlessness<br /> liver problems (hepatitis)<br /> low blood levels of sodium<br /> liver failure, yellowing of the skin and/or eyes (jaundice)<br /> severe skin reactions<br />Reporting of side effects<br />If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not<br />listed in this leaflet. You can also report side effects directly (see details below).By reporting<br />side effects, you can help provide more information on the safety of this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to<br />the last day of that month.<br />Do not store Arxia above 30&ordm; C.<br />Store in the original package in order to protect from moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is etoricoxib. Each film coated tablet contains 120 mg of etoricoxib.<br />The other ingredients are:<br />Core: pregelatinized maize starch, microcrystalline cellulose, croscarmellose sodium, colloidal<br />silicon dioxide, hidroxipropilcelullose, magnesium stearate.<br />Tablet coating: opadry Y-1-7000. The 120-mg tablets also contain iron oxide yellow (E172) and<br />indigo carmine lake (E132).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Arxia 120 mg film-coated tablets are pale-green, cylindrical, biconvex and engraved with code E12. Each
pack contains 7 tablets (in 1 blister pack.).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Laboratorios Cinfa, S.A.<br />Olaz-Chipi, 10 &ndash; Pol&iacute;gono Industrial Areta<br />31620 Huarte - Pamplona (Navarra) &ndash; Spain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2016.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أ ركسيا على المادة الفعالة إيتوريكوكسيب. ينتمي أ ركسيا إلى فئة من الأدوية تُدعى مثبطات إنزيم السيكلوأكسجيناز- 2 الانتقائية. وتنتمي هذه الفئة إلى مجموعة من الأدوية تُدعى الأدوية المضادة للالتهاب غير الستيرويدية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد أ ركسيا في خفض حدة الألم والتورم (الالتهاب) في المفاصل والعضلات في الأشخاص الذين يبلغون من العمر 16 عاماً فأكثر والذين يعانون من التهاب المفاصل، والتهاب المفاصل الرُوماتيزمي، و التهاب الفَقار التصلبي والنقْرس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويستعمل أ ركسيا في العلاج القصير الأمد للألم المتوسط الشدة الناجم عن إجراء عملية جراحية في الأسنان في الأشخاص الذين يبلغون من العمر 16 عاماً فأكثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تتناول أ ركسيا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (مُفرط التحسس) للإيتوريكوكسيب أو أي من المكونات الأخرى لهذا الدواء (المُدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية للأدوية المضادة للالتهاب غير الستيرويدية، ويشمل ذلك الأسبرين ومُثَبِّطات إنزيم السيكلوأكسجيناز-2 (انظر الآثار الجانبية المُحتملة، القسم 4).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قرحة في المعدة في الوقت الحالي أو من نزيف في المعدة أو الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي شديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كلوي شديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو هناك إمكانية لحدوث الحمل أو كنتِ مُرضعه (انظر &#39;الحمل، الإرضاع والخصوبة&#39;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت دون سن 16 عاماً</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء الأمعاء الالتهابي، مثل داء كُرون، أو التهاب القولون التقَرُّحي أو التهاب القولون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ارتفاع في ضغط الدم غير مُتحكَّم به عن طريق الأدوية (تحقق من طبيبك أو الممرضة إذا كنت غير متأكد ما إذا كان ضغط الدم لديك مضبوط بدرجة ملائمة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شخَّص طبيبك وجود مشاكل قلبية ويشمل ذلك فشل القلب (الأنواع المتوسطة الشدة أو الشديدة)، الذبحة الصدرية (ألم في الصدر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حدوث نوبة قلبية، أو خضعت لعملية تغير في الشرايين، أو أمراض الشرايين الطرفية (دورة دموية ضعيفة في الساقين أو القدم نتيجةً لتضيُّق الشرايين أو انسدادها)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حدوث السكتة الدماغية (ويشمل ذلك السكتة الدماغية الصُغرى، أو قصور وقتي في الدورة الدموية للمخ)</p><p dir="RTL">قد يزيد الإيتوريكوكسيب من خطر حدوث النوبات القلبية والسكتة الدماغية بدرجة طفيفة؛ ولهذا السبب لا ينبغي أن يُستخدم في هؤلاء المرضى المصابين فعلياَ بمشاكل قلبية أو سكتات دماغية .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أن أي من هذه ذات صلة لك، لا تأخذ أقراص حتى تستشير الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل البدء في تناول أ ركسيا إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي سابق لحدوث نزيف في المعدة أو قرحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص في السوائل، على سبيل المثال، ناجم عن نوبات طويلة من القيء أو الإسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تورم نتيجة لاحتباس السوائل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي سابق لحدوث فشل القلب، أو أي نوع آخر من الأمراض القلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي سابق لارتفاع ضغط الدم. فقد يزيد إيتوريكوكسيب ضغط الدم في بعض الأشخاص، خصوصاً عند تناوله بجرعات عالية، وسوف يرغب طبيبك في قياس ضغط الدم من وقت إلى آخر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضي سابق لأمراض في الكبد أو في الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية لعلاج العدوى. فقد يحجب إيتوريكوكسيب أو يُخفي حدوث ارتفاع درجة الحرارة، والذي يُعَد علامة على حدوث العدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السكري، أو ارتفاع مستويات الكوليسترول، أو كنت مدخناً. فقد تزيد هذه الحالات من خطر حدوث الأمراض القلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترغبين في حدوث الحمل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تبلغ من العمر 65 عاماً فأكثر.</p><p dir="RTL">إذا لم تكن متأكداً من عدم انطباق أيٍّ من الحالات المذكورة أعلاه على حالتك، <strong>فتحدث مع طبيبك قبل البدء في تناول أ ركسيا</strong> لمعرفة ما إذا كان هذا الدواء ملائماً لك.</p><p dir="RTL">يعمل إيتوريكوكسيب بشكل جيد في كبار السن والبالغين على حدٍّ سواء. إذا كان عمرك 65 عاماً فأكثر، فسوف يرغب طبيبك في المحافظة على فحصك بشكل ملائم. ليس هناك ضرورة لإجراء تعديل على الجرعة في المرضى الذين تزيد أعمارهم عن 65 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تُعطِ هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 16 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أو تناولت أو من المحتمل تناولك لأي أدوية أخرى، ويشمل ذلك الأدوية المتاحة بدون وصفة طبية.</p><p dir="RTL">وإذا ما كنت تتناول أياً من الأدوية التالية بشكل خاص، فقد يرغب طبيبك في مراقبة حالتك لفحص ما إذا كانت الأدوية تعمل مع بعضها بعضاً بشكل ملائم، بمجرد البدء في تناول أ ركسيا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على زيادة سيولة الدم (مضادات التخثر)، مثل الورافارين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريفامبيسين (مضاد حيوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثوتريكسات (وهو دواء يستخدم في&nbsp; كبت جهاز المناعة، وغالباً ما يُستخدم في علاج التهاب المفاصل الروماتيزمي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين أو التاكروليمُس (وهي أدوية تُستخدم في تثبيط جهاز المناعة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (وهو دواء يُستخدم في علاج بعض أنواع الاكتئاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تساعد في السيطرة على ارتفاع ضغط الدم وفشل القلب وتُدعى مثبطات الإنزيم المُحوِّل للأنجيوتنسين ومُحْصرات مُستقبلات الأنجيوتنسين، وتشمل الأمثلة الإينالابريل والراميبريل، واللوسارتان والفالسارتان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُدِرَّات البول (أقراص الماء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين (وهو دواء يُستخدم في علاج فشل القلب وعدم انتظام نَظْم القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المينوكسديل (وهو دواء يُستخدم في علاج ارتفاع ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص السالبوتامول أو المحلول الذي يُؤخذ عن طريق الفم (وهو دواء يُستخدم في علاج الربو)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص منع الحمل (قد يزيد الجمع بين الدوائين من خطر حدوث الآثار الجانبية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المعالجة التعويضية بالهرمونات (قد يزيد الجمع بين الدوائين من خطر حدوث الآثار الجانبية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسبرين، يزيد خطر حدوث قرحات المعدة في حال تناولك إيتوريكوكسيب بالتزامن مع الأسبرين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم الأسبرين للوقاية من حدوث النوبات القلبية أو السكتة:</p><p dir="RTL">من الممكن تناول إيتوريكوكسيب مع جرعة منخفضة من الأسبرين. فإذا ما كنت تتناول حالياً جرعة منخفضة من الأسبرين للوقاية من حدوث النوبات القلبية أو السكتة، فلا ينبغي عليك إيقاف تناول الأسبرين حتى تتحدث مع طبيبك في هذا الشأن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسبرين ومضادات الالتهاب غير الستيرويدية الأخرى:</p><p dir="RTL">لا تتناول جرعة عالية من الأسبرين أو من الأدوية المضادة للالتهاب غير الستيرويدية الأخرى أثناء تناولك لإيتوريكوكسيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أ ركسيا مع الطعام والشراب </strong></p><p dir="RTL">قد يبدأ تأثير الدواء بشكل أسرع عند تناوله على معدة فارغة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب عدم تناول أ ركسيا أثناء الحمل. وإذا كنتِ حاملاً أو تعتقدين بوجود حمل، أو تخططين لحدوث الحمل، فلا تتناولي الأقراص. وإذا كنتِ حاملاً، فأوقفي تناول الأقراص واستشيري طبيبك. وتحدثي إليه إذا كنتِ غير متأكدة أو كنتِ بحاجة إلى مزيد من النصائح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإرضاع</strong></p><p dir="RTL">من غير المعروف ما إذا كان أ ركسيا يُفرز في لبن الأم. فإذا ما كنتِ مرضعاً، أو تخططين لإرضاع طفلك، فاستشيري طبيبك قبل تناول أ ركسيا. وإذا كنتِ تستعملين أ ركسيا، فيجب عليكِ عدم إرضاع طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">لا يُوصى باستخدام أ ركسيا في النساء اللاتي يسعين لحدوث الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">أُبلغ عن حدوث الدوخة والنعاس في بعض الأشخاص الذين تناولوا إيتوريكوكسيب. لا تحاول القيادة إذا ما عانيتَ من حدوث الدوخة أو النعاس.</p><p dir="RTL">لا تحاول استخدام أي أدوات أو آلات إذا ما عانيتَ من حدوث الدوخة أو النعاس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>. كيفية استعمال أ ركسيا</strong></p><p dir="RTL">تناول أ ركسيا دائماً كما أخبرك طبيبك تماماً. ينبغي مراجعة طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">لا تتناول أكثر من الجرعة الموصى بها لحالتك. سوف يرغب طبيبك في مناقشة علاجك من وقت لآخر. ومن المهم أن تتناول أقل جرعة ممكنة يمكنها أن تسيطر على الألم الذي تعاني منه، ولا ينبغي تناول أ ركسيا لمدة أطول من المدة الضرورية لذلك. ويرجع هذا إلى إمكانية زيادة خطر حدوث النوبات القلبية أو السكتة بعد المعالجة الطويلة الأمد ، وخصوصاً في حالة تناول الجرعات العالية.</p><p dir="RTL">تتوافر عدة جرعات من هذا المستحضر الدوائي، وسوف يصف طبيبك جرعة القرص الملائم لعلاجكَ وفقاً لدرجة شدة مرضك.</p><p dir="RTL"><u>الجُرعة المُوصى بها:</u></p><p dir="RTL">التهاب المفاصل</p><p dir="RTL">تبلغ الجرعة الموصى بها 30 ملجم مرة واحدة يومياً، تزيد إلى 60 ملجم مرة واحدة يومياً بحدٍّ أقصى إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب المفاصل الروماتويدي</p><p dir="RTL">تبلغ الجرعة الموصى بها 60 ملجم مرة واحدة يومياً، تزيد إلى 90 ملجم مرة واحدة يومياً بحدٍّ أقصى إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب الفَقار التصلبى</p><p dir="RTL">تبلغ الجرعة الموصى بها 60 ملجم مرة واحدة يومياً، تزيد إلى 90 ملجم مرة واحدة يومياً بحدٍّ أقصى إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حالات الألم الحادة</p><p dir="RTL">ينبغي استخدام الإيتوريكوكسيب في فترة حدوث الألم الحاد فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">النقرس</p><p dir="RTL">تبلغ الجرعة الموصى بها120 ملجم مرة واحدة يومياً، والتي ينبغي أن تُستخدم أثناء فترة حدوث الألم الحاد فقط، وتقتصر على فترة معالجة تبلغ 8 أيام بحدٍّ أقصى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الألم التالي للجراحة السِّنية</p><p dir="RTL">تبلغ الجرعة الموصى بها 90 ملجم مرة واحدة يومياً، وتقتصر على فترة معالجة تبلغ 3 أيام بحدٍّ أقصى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشاكل فى الكبد</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي خفيف، فينبغي عليك عدم تناول أكثر من 60 ملجم في اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي متوسط الشدة، فينبغي عليك عدم تناول أكثر من 30 ملجم في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون والمراهقون</strong></p><p dir="RTL">يجب على الأطفال والمراهقين الذين تقل أعمارهم عن 16 عاماً عدم تناول أ ركسيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">ليس هناك ضرورة لإجراء تعديل على الجرعة التي يتناولها كبار السن. وكما هو الحال مع الأدوية الأخرى، ينبغي توخي الحذر عند استخدامه في المرضى المُسنين.</p><p dir="RTL">طريقة الأستخدام</p><p dir="RTL">إن أ ركسيا معد للاستخدام عن طريق الفم. تناول الأقراص مرة واحدة في اليوم. يمكن تناول أ ركسيا مع الطعام أو على معدة فارغة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال تناولك أكثر مما ينبغي من أ ركسيا</strong></p><p dir="RTL">يجب عليك ألا تتناول أكثر من عدد الأقراص التي أوصى الطبيب بتناولها. وإذا ما تناولت الكثير من أقراص أ ركسيا، يجب عليك طلب العناية الطبية في الحال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال نسيان تناول أ ركسيا</strong></p><p dir="RTL">من المهم أن تتناول أ ركسيا طبقاً لوصف الطبيب. إذا نسيت تناول الجرعة, فتابع النظام العلاجي المُعتاد&nbsp; في اليوم التالي. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">وإذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب أ ركسيا آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله.</p><p dir="RTL"><strong>إذا ما تطوَّرت أيٌّ من هذه العلامات، فيجب عليك إيقاف أ ركسيا واستشارة الطبيب في الحال (راجع ما يجب معرفته قبل تناول أركسيا &ndash; القسم 2):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النَّفَس، آلام في الصدر، أو ظهور تورم في الكاحل أو في حال تفاقم تورمه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين (اليَرَقان)- وتمثل هذه علامات على حدوث مشاكل فى الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد أو مستمر في المعدة أو في حال أصبح لون البراز داكناً</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي &ndash; والذي قد يشمل حدوث مشاكل جلدية مثل التقرحات والبثور، أو تورم الوجه، أو الشفتين, أو اللسان أو الحنجرة والتي قد تتسبب في حدوث صعوبة في التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعرف تكرار حدوث الآثار الجانبية المحتملة المذكورة أدناه باستخدام المصطلحات التالية:</p><p dir="RTL">شائعة جداً (تصيب أكثر من مريض واحد من كل 10 مرضى )</p><p dir="RTL">شائعة (تصيب من 1-10 مرضى من كل 100 مريض)</p><p dir="RTL">غير شائعة (تصيب من 1-10 مرضى من كل 1000 مريض)</p><p dir="RTL">نادرة الحدوث (تصيب من 1-10 مرضى من كل 10.000 مريض)</p><p dir="RTL">نادرة الحدوث جداً (تصيب أقل من مريض واحد من كل 10.000 مريض)</p><p dir="RTL">قد تحدث الآثار الجانبية التالية أثناء العلاج بأ ركسيا:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جداً</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سِنْخ جاف (التهاب وألم بعد خلع الأسنان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الساقين و/أو القدمين بسبب احتباس السوائل (وذمة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة، صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان (ضربات قلب سريعة أو غير منتظمة)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ا رتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزيز أو ضيق النَّفَس (تشنُّج قصبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، غازات بالبطن، التهاب المعدة (التهاب الغشاء المُبطِّن للمعدة)، حرقة المعدة، الإسهال، عسر الهضم، غثيان،&nbsp; القيء، التهاب المريء، قرحات الفم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبارات الدم المتعلقة بالكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث كدمات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وتعب شبيه باعراض الإنفلونزا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير</strong> <strong>شائعة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء (التهاب القناة الهضمية التي تشمل كلاً من المعدة والامعاء الدقيقة/ عدوى معدية)، عدوى الجهاز التنفسي العلوي، عدوى الجهاز البولي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في النتائج المختبرية (انخفاض في عدد خلايا الدم الحمراء، انخفاض في عدد خلايا الدم البيضاء، انخفاض في الصفائح الدموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية (تفاعل تحسسي ويشمل حدوث الشَرَى وهو ما يكون خطيراً بدرجة كافية تستدعي معها طلب العناية الصحية الفورية(</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية أو نقصانها، زيادة الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق، الاكتئاب، انخفاض التركيز؛ رؤية وسماع أشياء غير موجودة (هلاوس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في حاسة التذوق، عدم القدرة على النوم، التنميل أو الإحساس بالنخز، النعاس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، تهيج العين واحمرارها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين، دُوار (الإحساس بالدُوار دون تغيير الوضعية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال ضربات القلب (رَجَفان أذيني)، تسارع ضربات القلب، فشل القلب، الشعور بالضيق، ضغط أو ثِقَل في الصدر (الذبحة الصدرية)، نوبات قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه، سكتة دماغية، سكتة دماغية صُغرى (قصور وقتي في الدورة الدموية للمخ)، ارتفاع حاد في ضغط الدم، التهاب الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السُّعال، عُسْر التنفس، نزيف الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ المعدة أو الأمعاء، تغيرات في الوظائف الطبيعية للأمعاء، جفاف الفم، قرحة المعدة، التهاب الغشاء المُبطِّن للمعدة والذي قد يكون خطيراً مما يؤدي إلى حدوث النزيف، متلازمة القولون المُتهَيِّج (القولون العصبي)، التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، طفح جلدي أو حكة، احمرار الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مَغَص/تشنَّج العضلات، ألم/ تيبُّس العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كميات كبيرة من البوتاسيوم في الدم، تغيرات في نتائج اختبارات الدم أو البول المتعلقة بالكليتين، مشاكل كلوية خطيرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة الحدوث</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وَذَمة وعائية (تفاعل تحسسي يترافق مع حدوث تورم الوجه، الشفتين, اللسان و/أو الحنجرة والتي قد تتسبب في حدوث صعوبة في التنفس أو البلع، والتي قد تكون خطيرة بدرجة كافية مما يستدعي طلب العناية الطبية في الحال)/ تفاعلات&nbsp; فرط حساسية حاد و مفاجئ وتشمل حدوث صدمة (وهو عبا رة عن تفاعل تحسسي خطير يستدعي طلب العناية الطبية في الحال)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ا رتباك، قلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل كبدية (التهاب الكبد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد، اصفرار الجلد و/أو العينين (اليَرَقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية, فاستشر الطبيب أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة، يمكنك الإبلاغ عن الآثار الجانبية مبا شرة أيضاً (انظر التفاصيل أدناه). وبذلك، يمكنك المساعدة في تقديم معلومات أكثر حول أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العلبة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">لا تخزن أ ركسيا في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يرجى التخزين في العلبة الأصلية لحمايتها من الرطوبة.</p><p dir="RTL">لا ينبغي التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعمل. سوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحتوي أركسيا على</strong></p><ul><li dir="RTL">المادة الفعالة هي الإيتوريكوكسيب. يحتوي كل قرص مغلف على 120 ملجم من الإيتوريكوكسيب.</li><li dir="RTL">تشمل المكونات الأخرى:</li></ul><p dir="RTL">الطبقة الداخلية للقرص: نشا ذرة مُحول مسبقاَ الى جيلاتين، سليلوز دقيق البلورات، كروسكارميلوز الصوديوم, ثاني أكسيد السيليكون الغَرَواني، هيدروكسي بروبيل سليلوز، ستيارات المغنيزيوم.</p><p dir="RTL">غلاف القرص: أوبادري Y-1-7000، ويحتوي قرص ال 120 ملجم على أكسيد الحديد الأصفر(E-172)، والقرمز النيلي الأرجواني (E-132).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل ومحتويات علبة أركسيا</strong></p><p dir="RTL">أركسيا 120 ملجم أقراص مغلفة ذات لون أخضر فاتح، أسطوانية الشكل، محدبة الوجهين محفور عليها الرمز E12. تحتوي كل علبة على 7 أقراص (فى شريط واحد).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية</p><p dir="RTL">31620 أوارتي - بامبلونا (نافارا) - إسبانيا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل 2016.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arxia 120 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 120 mg of etoricoxib.
Excipients with known effect:
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets (tablets).
120 mg tablets: biconvex, cylindrical, pale green tablets engraved with E12 on one side containing
120 mg of etoricoxib.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ARXIA is indicated in adults and adolescents 16 years of age and older for the symptomatic<br />relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and<br />signs of inflammation associated with acute gouty arthritis.<br />ARXIA is indicated in adults and adolescents 16 years of age and older for the short-term<br />treatment of moderate pain associated with dental surgery.<br />The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the<br />individual patient&#39;s overall risks (see sections 4.3, 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the<br />shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s<br />need for symptomatic relief and response to therapy should be re-evaluated periodically,<br />especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).<br />Osteoarthritis<br />The recommended dose is 30 mg once daily. In some patients with insufficient relief from<br />symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an<br />increase in therapeutic benefit, other therapeutic options should be considered.<br />Rheumatoid arthritis<br />The recommended dose is 60 mg once daily. In some patients with insufficient relief from<br />symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is<br />clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the<br />absence of an increase in therapeutic benefit, other therapeutic options should be considered.<br />Ankylosing spondylitis<br />The recommended dose is 60 mg once daily. In some patients with insufficient relief from<br />symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is<br />clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the<br />absence of an increase in therapeutic benefit, other therapeutic options should be considered.<br />Acute pain conditions<br />For acute pain conditions, etoricoxib should be used only for the acute symptomatic period.<br />Acute gouty arthritis<br />The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis,<br />etoricoxib was given for 8 days.<br />Postoperative dental surgery pain<br />The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients<br />may require other postoperative analgesia in addition to ARXIA during the three day treatment<br />period.<br />Doses greater than those recommended for each indication have either not demonstrated<br />additional efficacy or have not been studied. Therefore:<br />The dose for OA should not exceed 60 mg daily.<br />The dose for RA and ankylosing spondylitis should not exceed 90 mg daily.<br />The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days<br />treatment.<br />The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a<br />maximum of 3 days.<br />Special populations<br />Elderly patients<br />No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be<br />exercised in elderly patients (see section 4.4).<br />Patients with hepatic impairment<br />Regardless of indication, in patients with mild hepatic dysfunction (Child-Pugh score 5-6) a dose<br />of 60 mg once daily should not be exceeded. In patients with moderate hepatic dysfunction<br />(Child-Pugh score 7-9), regardless of indication, the dose of 30 mg once daily should not be<br />exceeded.<br />Clinical experience is limited particularly in patients with moderate hepatic dysfunction and<br />caution is advised. There is no clinical experience in patients with severe hepatic dysfunction<br />(Child-Pugh score 􀂕10); therefore, its use is contra- indicated in these patients (see sections 4.3,<br />4.4 and 5.2).<br />Patients with renal impairment<br />No dosage adjustment is necessary for patients with creatinine clearance 􀂕30 ml/min (see<br />section 5.2). The use of etoricoxib in patients with creatinine clearance &lt;30 ml/min is<br />contra-indicated (see sections 4.3 and 4.4).<br />Paediatric population<br />Etoricoxib is contra-indicated in children and adolescents under 16 years of age (see section<br />4.3).<br />Method of administration<br />ARXIA is administered orally and may be taken with or without food. The onset of the effect of<br />the medicinal product may be faster when ARXIA is administered without food. This should be<br />considered when rapid symptomatic relief is needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Active peptic ulceration or active gastro-intestinal (GI) bleeding.
• Patients who, after taking acetylsalicylic acid or NSAIDs including COX-2
(cyclooxygenase-2) inhibitors, experience bronchospasm, acute rhinitis, nasal polyps,
angioneurotic oedema, urticaria, or allergic-type reactions.
• Pregnancy and lactation (see sections 4.6 and 5.3).
• Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 􀂕10).
• Estimated renal creatinine clearance <30 ml/min.
• Children and adolescents under 16 years of age.
• Inflammatory bowel disease.
• Congestive heart failure (NYHA II-IV).
• Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg
and has not been adequately controlled.
• Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular
disease.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastrointestinal effects<br />Upper gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them<br />resulting in fatal outcome, have occurred in patients treated with etoricoxib.<br />Caution is advised with treatment of patients most at risk of developing a gastrointestinal<br />complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid<br />concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and<br />GI bleeding.<br />There is a further increase in the risk of gastrointestinal adverse effects (gastrointestinal<br />ulceration or other gastrointestinal complications) when etoricoxib is taken concomitantly with<br />acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective<br />COX-2 inhibitors + acetylsalicylic acid vs. NSAIDs + acetylsalicylic acid has not been<br />demonstrated in long-term clinical trials (see section 5.1).<br />Cardiovascular effects<br />Clinical trials suggest that the selective COX-2 inhibitor class of drugs may be associated with a<br />risk of thrombotic events (especially myocardial infarction (MI) and stroke), relative to placebo<br />and some NSAIDs. As the cardiovascular risks of etoricoxib may increase with dose and<br />duration of exposure, the shortest duration possible and the lowest effective daily dose should be<br />used. The patient&#39;s need for symptomatic relief and response to therapy should be re- evaluated<br />periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).<br />Patients with significant risk factors for cardiovascular events (e.g. hypertension,<br />hyperlipidaemia, diabetes mellitus, smoking) should only be treated with etoricoxib after<br />careful consideration (see section 5.1).<br />COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of<br />cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect. Therefore<br />antiplatelet therapies should not be discontinued (see sections above, 4.5 and 5.1.).<br />Renal effects<br />Renal prostaglandins may play a compensatory role in the maintenance of renal perfusion.<br />Therefore, under conditions of compromised renal perfusion, administration of etoricoxib may<br />cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby<br />impair renal function. Patients at greatest risk of this response are those with pre-existing<br />significantly impaired renal function, uncompensated heart failure, or cirrhosis. Monitoring of<br />renal function in such patients should be considered.<br />Fluid retention, oedema and hypertension<br />As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention,<br />oedema and hypertension have been observed in patients taking etoricoxib. All Nonsteroidal<br />Anti-inflammatory Drugs (NSAIDs), including etoricoxib, can be associated with new onset or<br />recurrent congestive heart failure. For information regarding a dose related response for<br />etoricoxib see section 5.1. Caution should be exercised in patients with a history of cardiac<br />failure, left ventricular dysfunction, or hypertension and in patients with pre-existing oedema<br />from any other reason. If there is clinical evidence of deterioration in the condition of these<br />patients, appropriate measures including discontinuation of etoricoxib should be taken.<br />Etoricoxib may be associated with more frequent and severe hypertension than some other<br />NSAIDs and selective COX-2 inhibitors, particularly at high doses. Therefore, hypertension<br />should be controlled before treatment with etoricoxib (see section 4.3) and special attention<br />should be paid to blood pressure monitoring during treatment with etoricoxib. Blood pressure<br />should be monitored within two weeks after initiation of treatment and periodically thereafter. If<br />blood pressure rises significantly, alternative treatment should be considered.<br />Hepatic effects<br />Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)<br />(approximately three or more times the upper limit of normal) have been reported in<br />approximately 1% of patients in clinical trials treated for up to one year with etoricoxib 30, 60<br />and 90 mg daily.<br />Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal<br />liver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or<br />if persistently abnormal liver function tests (three times the upper limit of normal) are detected,<br />etoricoxib should be discontinued.<br />General<br />If during treatment, patients deteriorate in any of the organ system functions described above,<br />appropriate measures should be taken and discontinuation of etoricoxib therapy should be<br />considered. Medically appropriate supervision should be maintained when using etoricoxib in the<br />elderly and in patients with renal, hepatic, or cardiac dysfunction.<br />Caution should be used when initiating treatment with etoricoxib in patients with dehydration. It<br />is advisable to rehydrate patients prior to starting therapy with etoricoxib.<br />Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson<br />syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with<br />the use of NSAIDs and some selective COX-2 inhibitors during post-marketing surveillance (see<br />section 4.8). Patients appear to be at highest risk for these reactions early in the course of<br />therapy with the onset of the reaction occurring in the majority of cases within the first month of<br />treatment. Serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been<br />reported in patients receiving etoricoxib (see section 4.8). Some selective COX-2 inhibitors have<br />been associated with an increased risk of skin reactions in patients with a history of any drug<br />allergy. Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions,<br />or any other sign of hypersensitivity.<br />Etoricoxib may mask fever and other signs of inflammation.<br />Caution should be exercised when co-administering etoricoxib with warfarin or other oral<br />anticoagulants (see section 4.5).<br />The use of etoricoxib, as with any medicinal product known to inhibit cyclooxygenase /<br />prostaglandin synthesis, is not recommended in women attempting to conceive (see sections<br />4.6, 5.1, and 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />Oral anticoagulants: In subjects stabilised on chronic warfarin therapy, the administration of<br />etoricoxib 120 mg daily was associated with an approximate 13% increase in prothrombin time<br />International Normalised Ratio (INR). Therefore, patients receiving oral anticoagulants should be<br />closely monitored for their prothrombin time INR, particularly in the first few days when<br />therapy with etoricoxib is initiated or the dose of etoricoxib is changed (see section 4.4).<br />Diuretics, ACE inhibitors and Angiotensin II Antagonists: NSAIDs may reduce the effect of<br />diuretics and other antihypertensive drugs. In some patients with compromised renal function<br />(e.g. dehydrated patients or elderly patients with compromised renal function) the<br />co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit<br />cyclo-oxygenase may result in further deterioration of renal function, including possible acute<br />renal failure, which is usually reversible. These interactions should be considered in patients<br />taking etoricoxib concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore,<br />the combination should be administered with caution, especially in the elderly. Patients should<br />be adequately hydrated and consideration should be given to monitoring of renal function after<br />initiation of concomitant therapy, and periodically thereafter.<br />Acetylsalicylic Acid: In a study in healthy subjects, at steady state, etoricoxib 120 mg once<br />daily had no effect on the anti-platelet activity of acetylsalicylic acid (81 mg once daily).<br />Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular<br />prophylaxis (low-dose acetylsalicylic acid). However, concomitant administration of low-dose<br />acetylsalicylic acid with etoricoxib may result in an increased rate of GI ulceration or other<br />complications compared to use of etoricoxib alone. Concomitant administration of etoricoxib<br />with doses of acetylsalicylic acid above those for cardiovascular prophylaxis or with other<br />NSAIDs is not recommended (see sections 5.1 and 4.4.).<br />Cyclosporin and tacrolimus: Although this interaction has not been studied with etoricoxib,<br />coadministration of cyclosporin or tacrolimus with any NSAID may increase the nephrotoxic<br />effect of cyclosporin or tacrolimus. Renal function should be monitored when etoricoxib and<br />either of these drugs is used in combination.<br />Pharmacokinetic interactions<br />The effect of etoricoxib on the pharmacokinetics of other drugs<br />Lithium: NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels.<br />If necessary, monitor blood lithium closely and adjust the lithium dosage while the<br />combination is being taken and when the NSAID is withdrawn.<br />Methotrexate: Two studies investigated the effects of etoricoxib 60, 90 or 120 mg administered<br />once daily for seven days in patients receiving once-weekly methotrexate doses of 7.5 to 20 mg<br />for rheumatoid arthritis. Etoricoxib at 60 and 90 mg had no effect on methotrexate plasma<br />concentrations or renal clearance. In one study, etoricoxib 120 mg had no effect, but in the other<br />study, etoricoxib 120 mg increased methotrexate plasma concentrations by 28% and reduced<br />renal clearance of methotrexate by 13%. Adequate monitoring for methotrexate-related toxicity<br />is recommended when etoricoxib and methotrexate are administered concomitantly.<br />Oral contraceptives: Etoricoxib 60 mg given concomitantly with an oral contraceptive<br />containing 35 micrograms ethinyl estradiol (EE) and 0.5 to 1 mg norethindrone for 21 days<br />increased the steady state AUC0-24hr of EE by 37%. Etoricoxib 120 mg given with the same<br />oral contraceptive concomitantly or separated by 12 hours, increased the steady state<br />AUC0-24hr of EE by 50 to 60%. This increase in EE concentration should be considered when<br />selecting an oral contraceptive for use with etoricoxib. An increase in EE exposure can increase<br />the incidence of adverse events associated with oral contraceptives (e.g., venous<br />thrombo-embolic events in women at risk).<br />Hormone Replacement Therapy (HRT): Administration of etoricoxib 120 mg with hormone<br />replacement therapy consisting of conjugated estrogens (0.625 mg PREMARINTM) for 28 days,<br />increased the mean steady state AUC0-24hr<br />of unconjugated estrone (41%), equilin (76%), and 17-􀈕-estradiol (22%). The effect of the<br />recommended chronic doses of etoricoxib (30, 60, and 90 mg) has not been studied. The effects<br />of etoricoxib 120 mg on the exposure (AUC0-24hr) to these estrogenic components of<br />PREMARIN were less than half of those observed when PREMARIN was administered alone<br />and the dose was increased from 0.625 to 1.25 mg. The clinical significance of these increases is<br />unknown, and higher doses of PREMARIN were not studied in combination with etoricoxib.<br />These increases in estrogenic<br />concentration should be taken into consideration when selecting post-menopausal hormone<br />therapy for use with etoricoxib because the increase in oestrogen exposure might increase the<br />risk of adverse events associated with HRT.<br />Prednisone/prednisolone: In drug-interaction studies, etoricoxib did not have clinically<br />important effects on the pharmacokinetics of prednisone/prednisolone.<br />Digoxin: Etoricoxib 120 mg administered once daily for 10 days to healthy volunteers did not<br />alter the steady-state plasma AUC0-24hr or renal elimination of digoxin. There was an increase<br />in digoxin Cmax (approximately 33%). This increase is not generally important for most<br />patients. However, patients at high risk of digoxin toxicity should be monitored for this when<br />etoricoxib and digoxin are administered concomitantly.<br />Effect of etoricoxib on drugs metabolised by sulfotransferases<br />Etoricoxib is an inhibitor of human sulfotransferase activity, particularly SULT1E1, and has<br />been shown to increase the serum concentrations of ethinyl estradiol. While knowledge about<br />effects of multiple sulfotransferases is presently limited and the clinical consequences for many<br />drugs are still being examined, it may be prudent to exercise care when administering<br />etoricoxib concurrently with other drugs primarily metabolised by human sulfotransferases (e.g.,<br />oral salbutamol and minoxidil).<br />Effect of etoricoxib on drugs metabolised by CYP isoenzymes<br />Based on in vitro studies, etoricoxib is not expected to inhibit cytochromes P450 (CYP) 1A2,<br />2C9, 2C19, 2D6, 2E1 or 3A4. In a study in healthy subjects, daily administration of etoricoxib<br />120 mg did not alter hepatic CYP3A4 activity as assessed by the erythromycin breath test.<br />Effects of other drugs on the pharmacokinetics of etoricoxib<br />The main pathway of etoricoxib metabolism is dependent on CYP enzymes. CYP3A4 appears<br />to contribute to the metabolism of etoricoxib in vivo. In vitro studies indicate that CYP2D6,<br />CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their<br />quantitative roles have not been studied in vivo.<br />Ketoconazole: Ketoconazole, a potent inhibitor of CYP3A4, dosed at 400 mg once a day for 11<br />days to healthy volunteers, did not have any clinically important effect on the single-dose<br />pharmacokinetics of 60 mg etoricoxib (43% increase in AUC).<br />Voriconazole and Miconazole: Co-administration of either oral voriconazole or topical<br />miconazole oral gel, strong CYP3A4 inhibitors, with etoricoxib caused a slight increase in<br />exposure to etoricoxib, but is not considered to be clinically meaningful based on published<br />data.<br />Rifampicin: Co-administration of etoricoxib with rifampicin, a potent inducer of CYP enzymes,<br />produced a 65% decrease in etoricoxib plasma concentrations. This interaction may result in<br />recurrence of symptoms when etoricoxib is co- administered with rifampicin. While this<br />information may suggest an increase in dose, doses of etoricoxib greater than those listed for<br />each indication have not been studied in combination with rifampicin and are therefore not<br />recommended (see section 4.2).<br />Antacids: Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant<br />extent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />No clinical data on exposed pregnancies are available for etoricoxib. Studies in animals have<br />shown reproductive toxicity (see section 5.3). The potential for human risk in pregnancy is<br />unknown. Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may<br />cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.<br />Etoricoxib is contraindicated in pregnancy (see section 4.3). If a woman becomes pregnant<br />during treatment, etoricoxib must be discontinued.<br />Breastfeeding<br />It is not known whether etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk<br />of lactating rats. Women who use etoricoxib must not breast feed (see sections 4.3 and 5.3).<br />Fertility<br />The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended<br />in women attempting to conceive. Effects on ability to drive and use machines<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizziness, vertigo or somnolence while taking etoricoxib should refrain<br />from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials, etoricoxib was evaluated for safety in 9,295 individuals, including 6,757<br />patients with OA, RA, chronic low back pain or ankylosing spondylitis (approximately 600<br />patients with OA or RA were treated for one year or longer).<br />In clinical studies, the undesirable effects profile was similar in patients with OA or RA treated<br />with etoricoxib for one year or longer.<br />In a clinical study for acute gouty arthritis, patients were treated with etoricoxib 120 mg once<br />daily for eight days. The adverse experience profile in this study was generally similar to that<br />reported in the combined OA, RA, and chronic low back pain studies.<br />In a cardiovascular safety outcomes programme of pooled data from three active comparator<br />controlled trials, 17, 412 patients with OA or RA were treated with etoricoxib (60 mg or 90<br />mg) for a mean duration of approximately 18 months. The safety data and details from this<br />programme are presented in section 5.1.<br />In clinical studies for acute postoperative dental pain following surgery including 614 patients<br />treated with etoricoxib (90 mg or 120 mg), the adverse experience profile in these studies was<br />generally similar to that reported in the combined OA, RA, and chronic low back pain studies.<br />Tabulated list of adverse reactions<br />The following undesirable effects were reported at an incidence greater than placebo in clinical<br />trials in patients with OA, RA, chronic low back pain or ankylosing spondylitis treated with<br />etoricoxib 30 mg, 60 mg or 90 mg up to the recommended dose for up to 12 weeks; in the<br />MEDAL Programme studies for up to 3&frac12; years; in short term acute pain studies for up to 7<br />days; or in post-marketing experience (see Table 1):<br />Table 1:<br />System Organ Class Adverse Reactions Frequency<br />C<br />Infections and infestations alveolar osteitis Common<br />gastroenteritis, upper respiratory infection,<br />urinary tract infection<br />Uncommon<br />Blood and lymphatic system<br />disorders<br />anaemia (primarily associated with<br />gastrointestinal bleeding), leukopenia,<br />thrombocytopenia<br />Uncommon<br />Immune system disorders hypersensitivity&Dagger; &szlig; Uncommon<br />angioedema/anaphylactic /anaphylactoid<br />reactions including shock&Dagger;<br />Rare<br />Metabolism and nutrition disorders oedema/fluid retention Common<br />appetite increase or decrease, weight gain Uncommon<br />Psychiatric disorders anxiety, depression, mental acuity decreased,<br />hallucinations&Dagger;<br />Uncommon<br />confusion&Dagger;, restlessness&Dagger; Rare<br />Nervous system disorders dizziness, headache Common<br />dysgeusia, insomnia,<br />paresthaesia/hypaesthesia, somnolence<br />Uncommon<br />Eye disorders blurred vision, conjunctivitis Uncommon<br />Ear and labyrinth disorders tinnitus, vertigo Uncommon<br />Cardiac disorders palpitations, arrhythmia&Dagger; Common<br />atrial fibrillation, tachycardia&Dagger;, congestive<br />heart failure, non-specific ECG changes,<br />angina pectoris&Dagger;, myocardial infarction&sect;<br />Uncommon<br />Vascular disorders hypertension Common<br />flushing, cerebrovascular accident&sect;, transient<br />ischaemic attack, hypertensive crisis&Dagger;,<br />vasculitis&Dagger;<br />Uncommon<br />Respiratory, thoracic and<br />mediastinal disorders<br />bronchospasm&Dagger; Common<br />cough, dyspnoea, epistaxis Uncommon<br />Gastrointestinal disorders abdominal pain Very<br />Constipation, flatulence, gastritis,<br />heartburn/acid reflux, diarrhea,<br />dyspepsia/epigastric discomfort, nausea,<br />vomiting, oesophagitis, oral ulcer<br />Common<br />abdominal distention, bowel movement pattern<br />change, dry mouth, gastroduodenal ulcer,<br />peptic ulcers including gastrointestinal<br />perforation and bleeding, irritable bowel<br />syndrome, pancreatitis&Dagger;<br />Uncommon<br />Hepatobiliary disorders ALT increased, AST increased Common<br />hepatitis&Dagger; Rare<br />hepatic failure&Dagger;, jaundice&Dagger; Rare&dagger;<br />Skin and subcutaneous tissue<br />disorders<br />ecchymosis Common<br />facial oedema, pruritus, rash, erythema&Dagger;,<br />urticaria&Dagger;<br />Uncommon<br />Stevens-Johnson syndrome&Dagger;, toxic epidermal<br />necrolysis&Dagger;, fixed drug eruption&Dagger;<br />Rare&dagger;<br />Musculoskeletal and connective<br />tissue disorders<br />muscular cramp/spasm, musculoskeletal<br />pain/stiffness<br />Uncommon<br />Renal and urinary disorders proteinuria, serum creatinine increased, renal<br />failure/renal insufficiency&Dagger;(see section 4.4)<br />Uncommon<br />General disorders and<br />administration site conditions<br />asthenia/fatigue, flu-like disease Common<br />chest pain Uncommon<br />Investigations blood urea nitrogen increased, creatine<br />phosphokinase increased, hyperkalaemia, uric<br />acid increased<br />Uncommon<br />blood sodium decreased Rare<br />*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in<br />the clinical trials data base: Very Common (􀂕1/10), Common (􀂕1/100 to &lt;1/10), Uncommon<br />(􀂕1/1000 to &lt;1/100), Rare (􀂕1/10,000 to<br />&lt;1/1000), Very Rare (&lt;1/10,000).<br />&Dagger; This adverse reaction was identified through post-marketing surveillance. Its reported<br />frequency has been estimated based upon the highest frequency observed across clinical trial<br />data pooled by indication and approved dose.<br />The frequency category of &ldquo;Rare&rdquo; was defined per the Summary of Product Characteristics<br />(SmPC) guidance (rev. 2, Sept 2009) on the basis of an estimated upper bound of the 95%<br />confidence interval for 0 events given the number of subjects treated with ARXIA in the<br />analysis of the Phase III data pooled by dose and indication (n=15,470).<br />&szlig; Hypersensitivity includes the terms &quot;allergy&quot;, &quot;drug allergy&quot;, &quot;drug hypersensitivity&quot;,<br />&quot;hypersensitivity&quot;, &quot;hypersensitivity NOS&quot;, &quot;hypersensitivity reaction&quot; and &quot;nonspecific<br />allergy&quot;.<br />&sect;Based on analyses of long-term placebo and active controlled clinical trials, selective COX-2<br />inhibitors have been associated with an increased risk of serious thrombotic arterial events,<br />including myocardial infarction and stroke. The absolute risk increase for such events is<br />unlikely to exceed 1% per year based on existing data (uncommon).<br />The following serious undesirable effects have been reported in association with the use of<br />NSAIDs and cannot be ruled out for etoricoxib: nephrotoxicity including interstitial nephritis<br />and nephrotic syndrome.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important.<br />It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />To report any side effect(s):<br />􀃭 The National Pharmacovigilance and Drug Safety Centre (NPC)<br />􀁸 Fax: +966-11-205-7662<br />􀁸 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />􀁸 Toll free phone: 8002490000<br />􀁸 E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, administration of single doses of etoricoxib up to 500 mg and multiple doses<br />up to 150 mg/day for 21 days did not result in significant toxicity. There have been reports of<br />acute overdosage with etoricoxib, although adverse experiences were not reported in the<br />majority of cases. The most frequently observed adverse experiences were consistent with the<br />safety profile for etoricoxib (e.g. gastrointestinal events, cardiorenal events).<br />In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove<br />unabsorbed material from the GI tract, employ clinical monitoring, and institute supportive<br />therapy, if required.<br />Etoricoxib is not dialysable by haemodialysis; it is not known whether etoricoxib is dialysable<br />by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids,<br />coxibs, ATC code: M01 AH05 Mechanism of Action<br />Etoricoxib is an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor within the clinical dose<br />range.<br />Across clinical pharmacology studies, ARXIA produced dose-dependent inhibition of COX-2<br />without inhibition of COX- 1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric<br />prostaglandin synthesis and had no effect on platelet function.<br />Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and<br />COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be<br />induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the<br />synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in<br />ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and<br />central nervous system functions (fever induction, pain perception and cognitive function). It<br />may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers<br />in man but its relevance to ulcer healing has not been established.<br />Clinical efficacy and safety Efficacy<br />In patients with osteoarthritis (OA), etoricoxib 60 mg once daily provided significant<br />improvements in pain and patient assessments of disease status. These beneficial effects were<br />observed as early as the second day of therapy and maintained for up to 52 weeks. Studies with<br />etoricoxib 30 mg once daily demonstrated efficacy superior to placebo over a 12 week<br />treatment period (using similar assessments as the above studies). In a dose ranging study,<br />etoricoxib 60 mg demonstrated significantly greater improvement than 30 mg for all 3 primary<br />endpoints over 6 weeks of treatment. The 30 mg dose has not been studied in osteoarthritis of<br />hands.<br />In patients with rheumatoid arthritis (RA), etoricoxib 60 mg and 90 mg once daily both provided<br />significant improvements in pain, inflammation, and mobility. In studies evaluating the 60 mg<br />and 90 mg dose, these beneficial effects were maintained over the 12-week treatment periods. In<br />a study evaluating the 60 mg dose compared to the 90 mg dose, etoricoxib 60 mg once daily<br />and 90 mg once daily were both more effective than placebo. The 90 mg dose was superior to<br />the 60 mg dose for Patient Global Assessment of Pain (0-100mm visual analogue scale), with an<br />average improvement of -2.71 mm (95% CI: -4.98 mm, -0.45 mm).<br />In patients experiencing attacks of acute gouty arthritis, etoricoxib 120 mg once daily over an<br />eight-day treatment period, relieved moderate to extreme joint pain and inflammation<br />comparable to indomethacin 50 mg three times daily. Pain<br />relief was observed as early as four hours after initiation of treatment.<br />In patients with ankylosing spondylitis, etoricoxib 90 mg once daily provided significant<br />improvements in spine pain, inflammation, stiffness and function. The clinical benefit of<br />etoricoxib was observed as early as the second day of therapy after initiation of treatment and<br />was maintained throughout the 52-week treatment period. In a second study evaluating the 60 mg<br />dose compared to the 90 mg dose, etoricoxib 60 mg daily and 90 mg daily demonstrated similar<br />efficacy compared to naproxen 1,000 mg daily. Among inadequate responders to 60 mg daily for<br />6 weeks, dose escalation to 90 mg daily improved spinal pain intensity score (0-100 mm visual<br />analogue scale) compared to continuing on 60 mg daily, with an average improvement of -2.70<br />mm (95% CI: -4.88 mm, -0.52 mm).<br />In a clinical study evaluating postoperative dental pain, etoricoxib 90 mg was administered once<br />daily for up to three days. In the subgroup of patients with moderate pain at baseline, etoricoxib<br />90 mg demonstrated a similar analgesic effect to that of ibuprofen 600 mg (16.11 vs. 16.39;<br />P=0.722), and greater than that of paracetamol/codeine 600 mg/60 mg (11.00; P&lt;0.001) and<br />placebo (6.84; P&lt;0.001) as measured by total pain relief over the first 6 hours (TOPAR6). The<br />proportion of patients reporting rescue medication usage within the first 24 hours of dosing was<br />40.8% for etoricoxib 90 mg, 25.5% for ibuprofen 600 mg Q6h, and 46.7% for<br />paracetamol/codeine 600 mg/60 mg Q6h compared to 76.2% for placebo. In this study, the<br />median onset of action (perceptible pain relief) of 90 mg etoricoxib was 28 minutes after<br />dosing.<br />Safety<br />Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Programme<br />The MEDAL Programme was a prospectively designed Cardiovascular (CV) Safety Outcomes<br />Programme of pooled data from three randomized, double-blind active comparator controlled<br />trials, the MEDAL study, EDGE II and EDGE.<br />The MEDAL Study, was an endpoint driven CV Outcomes study in 17,804 OA and 5,700 RA<br />patients treated with etoricoxib 60 (OA) or 90 mg (OA and RA) or diclofenac 150 mg daily for<br />a mean period of 20.3 months (maximum of 42.3 months, median 21.3 months). In this trial,<br />only serious adverse events and discontinuations due to any adverse events were recorded.<br />The EDGE and EDGE II studies compared the gastrointestinal tolerability of etoricoxib versus<br />diclofenac. The EDGE study included 7,111 OA patients treated with a dose of etoricoxib 90<br />mg daily (1.5 times the dose recommended for OA) or diclofenac 150 mg daily for a mean<br />period of 9.1 months (maximum 16.6 months, median 11.4 months). The EDGE II study<br />included 4,086 RA patients treated with etoricoxib 90 mg daily or diclofenac 150 mg daily for a<br />mean period of 19.2 months (maximum 33.1 months, median 24 months).<br />In the pooled MEDAL Programme, 34,701 patients with OA or RA were treated for a mean<br />duration of 17.9 months (maximum 42.3 months, median 16.3 months) with approximately<br />12,800 patients receiving treatment for more than 24 months. Patients enrolled in the<br />Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline.<br />Patients with a recent history of myocardial infarction, coronary artery bypass grafting or<br />percutaneous coronary intervention within 6 months preceding enrollment were excluded. Use<br />of gastroprotective agents and low dose aspirin were permitted in the studies.<br />Overall Safety:<br />There was no significant difference between etoricoxib and diclofenac in the rate of<br />cardiovascular thrombotic events. Cardiorenal adverse events were observed more frequently<br />with etoricoxib than with diclofenac, and this effect was dose- dependent (see specific results<br />below). Gastrointestinal and hepatic adverse events were observed significantly more frequently<br />with diclofenac than etoricoxib. The incidence of adverse experiences in EDGE and EDGE II<br />and of adverse experiences considered serious or resulting in discontinuation in the MEDAL<br />study was higher with etoricoxib than diclofenac.<br />Cardiovascular safety results:<br />The rate of confirmed thrombotic cardiovascular serious adverse events (consisting of cardiac,<br />cerebrovascular, and peripheral vascular events) was comparable between etoricoxib and<br />diclofenac, and data are summarized in the table below. There were no statistically significant<br />differences in thrombotic event rates between etoricoxib and diclofenac across all subgroups<br />analyzed including patient categories across a range of baseline cardiovascular risk. When<br />considered separately, the relative risks for confirmed thrombotic cardiovascular serious adverse<br />events with etoricoxib 60 mg or 90 mg compared with diclofenac 150 mg were similar.<br />Table 2: Rates of Confirmed Thrombotic CV Events (Pooled MEDAL Programme)<br />Etoricoxib (N=16,819)<br />25,836 Patient-Years<br />Diclofenac (N=16,483)<br />24,766 Patient-Years<br />Between<br />Treatment<br />Comparison<br />Rate&dagger; (95% CI) Rate&dagger; (95% CI) Relative Risk<br />(95% CI)<br />Confirmed Thrombotic Cardiovascular Serious Adverse Events<br />Per-protocol 1.24 (1.11, 1.38) 1.30 (1.17, 1.45) 0.95 (0.81, 1.11)<br />Intent-to-treat 1.25 (1.14, 1.36) 1.19 (1.08, 1.30) 1.05 (0.93, 1.19)<br />Confirmed Cardiac Events<br />Per-protocol 0.71 (0.61, 0.82) 0.78 (0.68, 0.90) 0.90 (0.74, 1.10)<br />Intent-to-treat 0.69 (0.61, 0.78) 0.70 (0.62, 0.79) 0.99 (0.84, 1.17)<br />Confirmed Cerebrovascular Events<br />Per-protocol 0.34 (0.28, 0.42) 0.32 (0.25, 0.40) 1.08 (0.80, 1.46)<br />Intent-to-treat 0.33 (0.28, 0.39) 0.29 (0.24, 0.35) 1.12 (0.87, 1.44)<br />Confirmed Peripheral Vascular Events<br />Per-protocol 0.20 (0.15, 0.27) 0.22 (0.17, 0.29) 0.92 (0.63, 1.35)<br />Intent-to-treat 0.24 (0.20, 0.30) 0.23 (0.18, 0.28) 1.08 (0.81, 1.44)<br />&dagger;Events per 100 Patient-Years; CI=confidence interval<br />N=total number of patients included in Per-protocol population<br />Per-protocol: all events on study therapy or within 14 days of discontinuation (excluded: patients<br />who took &lt; 75% of their study medication or took non-study NSAIDs &gt;10% of the time).<br />Intent-to-treat: all confirmed events up to the end of the trial (included patients potentially exposed<br />to non-study interventions following discontinuation of study medication). Total number of<br />patients randomised, n= 17,412 on etoricoxib and 17,289 on diclofenac.<br />CV mortality, as well as overall mortality, was similar between the etoricoxib and diclofenac<br />treatment groups. Cardiorenal Events:<br />Approximately 50% of patients enrolled in the MEDAL study had a history of hypertension at<br />baseline. In the study, the incidence of discontinuations due to hypertension-related adverse<br />events was statistically significantly higher for etoricoxib than for diclofenac. The incidence of<br />congestive heart failure adverse events (discontinuations and serious events) occurred at similar<br />rates on etoricoxib 60 mg compared to diclofenac 150 mg but was higher for etoricoxib 90 mg<br />compared to diclofenac 150 mg (statistically significant for 90 mg etoricoxib vs. 150 mg<br />diclofenac in MEDAL OA<br />cohort). The incidence of confirmed congestive heart failure adverse events (events that were<br />serious and resulted in hospitalisation or a visit to an emergency department) was<br />non-significantly higher with etoricoxib than diclofenac 150 mg, and this effect was<br />dose-dependent. The incidence of discontinuations due to oedema-related adverse events was<br />higher for etoricoxib than diclofenac 150 mg, and this effect was dose-dependent (statistically<br />significant for etoricoxib 90 mg, but not for etoricoxib 60 mg).<br />The cardiorenal results for EDGE and EDGE II were consistent with those described for the<br />MEDAL Study.<br />In the individual MEDAL Programme studies, for etoricoxib (60 mg or 90 mg), the absolute<br />incidence of discontinuation in any treatment group was up to 2.6% for hypertension, up to<br />1.9% for oedema, and up to 1.1% for congestive heart failure, with higher rates of<br />discontinuation observed with etoricoxib 90 mg than etoricoxib 60 mg.<br />MEDAL Programme Gastrointestinal Tolerability Results:<br />A significantly lower rate of discontinuations of treatment for any clinical (e.g., dyspepsia,<br />abdominal pain, ulcer) GI adverse event was observed with etoricoxib compared with diclofenac<br />within each of the three component studies of the MEDAL Programme. The rates of<br />discontinuations due to adverse clinical GI events per hundred patient-years over the entire<br />period of study were as follows: 3.23 for etoricoxib and 4.96 for diclofenac in the MEDAL<br />Study; 9.12 with etoricoxib and 12.28 with diclofenac in the EDGE study; and 3.71 with<br />etoricoxib and 4.81 with diclofenac in the EDGE II study.<br />MEDAL Programme Gastrointestinal Safety Results:<br />Overall upper GI events were defined as perforations, ulcers and bleeds. The subset of overall<br />upper GI events considered complicated included perforations, obstructions, and complicated<br />bleeding; the subset of upper GI events considered uncomplicated included uncomplicated<br />bleeds and uncomplicated ulcers. A significantly lower rate of overall upper GI events was<br />observed with etoricoxib compared to diclofenac. There was no significant difference between<br />etoricoxib and diclofenac in the rate of complicated events. For the subset of upper GI<br />haemorrhage events (complicated and uncomplicated combined), there was no significant<br />difference between etoricoxib and diclofenac. The upper GI benefit for etoricoxib compared<br />with diclofenac was not statistically significant in patients taking concomitant low-dose aspirin<br />(approximately 33% of patients).<br />The rates per hundred patient-years of confirmed complicated and uncomplicated upper GI<br />clinical events (perforations, ulcers and bleeds (PUBs)) were 0.67 (95% CI 0.57, 0.77) with<br />etoricoxib and 0.97 (95% CI 0.85, 1.10) with diclofenac,<br />yielding a relative risk of 0.69 (95% CI 0.57, 0.83).<br />The rate for confirmed upper GI events in elderly patients was evaluated and the largest reduction<br />was observed in patients 􀂕 75 years of age (1.35 [95% CI 0.94, 1.87] vs. 2.78 [95% CI 2.14,<br />3.56] events per hundred patient-years for etoricoxib and diclofenac, respectively.<br />The rates of confirmed lower GI clinical events (small or large bowel perforation, obstruction, or<br />haemorrhage, (POBs)) were not significantly different between etoricoxib and diclofenac.<br />MEDAL Programme Hepatic Safety Results:<br />Etoricoxib was associated with a statistically significantly lower rate of discontinuations due to<br />hepatic-related adverse experiences than diclofenac. In the pooled MEDAL Programme, 0.3%<br />of patients on etoricoxib and 2.7% of patients on diclofenac discontinued due to hepatic-related<br />adverse experiences. The rate per hundred patient-years was 0.22 on etoricoxib and 1.84 for<br />diclofenac (p-value was &lt;0.001 for etoricoxib vs. diclofenac). However, most hepatic adverse<br />experiences in the MEDAL Programme were non-serious.<br />Additional Thrombotic Cardiovascular Safety Data<br />In clinical studies excluding the MEDAL Programme Studies, approximately 3,100 patients<br />were treated with etoricoxib<br />􀂕60 mg daily for 12 weeks or longer. There was no discernible difference in the rate of confirmed<br />serious thrombotic cardiovascular events between patients receiving etoricoxib 􀂕60 mg, placebo,<br />or non-naproxen NSAIDs. However, the rate of these events was higher in patients receiving<br />etoricoxib compared with those receiving naproxen 500 mg twice daily. The difference in<br />antiplatelet activity between some COX-1 inhibiting NSAIDs and selective COX-2 inhibitors<br />may be of clinical significance in patients at risk of thrombo-embolic events. Selective COX-2<br />inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin<br />without affecting platelet thromboxane. The clinical relevance of these observations has not<br />been established.<br />Additional Gastrointestinal Safety Data<br />In two 12-week double-blind endoscopy studies, the cumulative incidence of gastroduodenal<br />ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in<br />patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily.<br />Etoricoxib had a higher incidence of ulceration as compared to placebo.<br />Renal Function Study in the Elderly<br />A randomized, double-blind, placebo-controlled, parallel-group study evaluated the effects of 15<br />days of treatment of etoricoxib (90 mg), celecoxib (200 mg bid), naproxen (500 mg bid) and<br />placebo on urinary sodium excretion, blood pressure, and other renal function parameters in<br />subjects 60 to 85 years of age on a 200-mEq/day sodium diet.<br />Etoricoxib, celecoxib, and naproxen had similar effects on urinary sodium excretion over the 2<br />weeks of treatment. All active comparators showed an increase relative to placebo with respect<br />to systolic blood pressures; however, etoricoxib was associated with a statistically significant<br />increase at Day 14 when compared to celecoxib and naproxen (mean change from baseline for<br />systolic blood pressure: etoricoxib 7.7 mmHg, celecoxib 2.4 mmHg, naproxen 3.6 mmHg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Orally administered etoricoxib is well absorbed. The absolute bioavailability is approximately<br />100%. Following 120 mg once-daily dosing to steady state, the peak plasma concentration<br />(geometric mean Cmax = 3.6 &mu;g/ml) was observed at approximately 1 hour (Tmax) after<br />administration to fasted adults. The geometric mean area under the curve (AUC0-24hr) was 37.8<br />&mu;g&bull;hr/ml. The pharmacokinetics of etoricoxib are linear across the clinical dose range.<br />Dosing with food (a high-fat meal) had no effect on the extent of absorption of etoricoxib after<br />administration of a 120-mg dose. The rate of absorption was affected, resulting in a 36%<br />decrease in Cmax and an increase in Tmax by 2 hours.<br />These data are not considered clinically significant. In clinical trials, etoricoxib was<br />administered without regard to food intake.<br />Distribution<br />Etoricoxib is approximately 92% bound to human plasma protein over the range of<br />concentrations of 0.05 to 5 &mu;g/ml. The volume of distribution at steady state (Vdss) was<br />approximately 1,20l in humans.<br />Etoricoxib crosses the placenta in rats and rabbits, and the blood-brain barrier in rats.<br />Biotransformation<br />Etoricoxib is extensively metabolised with &lt;1% of a dose recovered in urine as the parent drug.<br />The major route of metabolism to form the 6&#39;-hydroxymethyl derivative is catalyzed by CYP<br />enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib in vivo. In vitro<br />studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main<br />metabolic pathway, but their quantitative roles in vivo have not been studied.<br />Five metabolites have been identified in man. The principal metabolite is the 6&#39;-carboxylic acid<br />derivative of etoricoxib formed by further oxidation of the 6&#39;-hydroxymethyl derivative. These<br />principal metabolites either demonstrate no measurable activity or are only weakly active as<br />COX-2 inhibitors. None of these metabolites inhibit COX-1.<br />Elimination<br />Following administration of a single 25-mg radiolabeled intravenous dose of etoricoxib to healthy<br />subjects, 70% of radioactivity was recovered in urine and 20% in faeces, mostly as<br />metabolites. Less than 2% was recovered as unchanged drug.<br />Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal<br />excretion. Steady state concentrations of etoricoxib are reached within seven days of once daily<br />administration of 120 mg, with an accumulation ratio of approximately 2, corresponding to a<br />half-life of approximately 22 hours. The plasma clearance after a 25-mg intravenous dose is<br />estimated to be approximately 50 ml/min.<br />Characteristics in patients<br />Elderly patients: Pharmacokinetics in the elderly (65 years of age and older) are similar to those<br />in the young. Gender: The pharmacokinetics of etoricoxib are similar between men and women.<br />Hepatic impairment: Patients with mild hepatic dysfunction (Child-Pugh score 5-6)<br />administered etoricoxib 60 mg once daily had an approximately 16% higher mean AUC as<br />compared to healthy subjects given the same regimen. Patients with moderate hepatic<br />dysfunction (Child-Pugh score 7-9) administered etoricoxib 60 mg every other day had similar<br />mean AUC to the healthy subjects given etoricoxib 60 mg once daily; etoricoxib 30 mg once<br />daily has not been studied in this population. There are no clinical or pharmacokinetic data in<br />patients with severe hepatic dysfunction (Child-Pugh score 􀂕10). (See sections 4.2 and 4.3.)<br />Renal impairment: The pharmacokinetics of a single dose of etoricoxib 120 mg in patients with<br />moderate to severe renal insufficiency and patients with end-stage renal disease on<br />haemodialysis were not significantly different from those in healthy subjects. Haemodialysis<br />contributed negligibly to elimination (dialysis clearance approximately 50 ml/min). (See<br />sections 4.3 and 4.4.)<br />Paediatric patients: The pharmacokinetics of etoricoxib in paediatric patients (&lt;12 years old)<br />have not been studied.<br />In a pharmacokinetic study (n=16) conducted in adolescents (aged 12 to 17) the<br />pharmacokinetics in adolescents weighing 40 to 60 kg given etoricoxib 60 mg once daily and<br />adolescents &gt;60 kg given etoricoxib 90 mg once daily were similar to the pharmacokinetics in<br />adults given etoricoxib 90 mg once daily. Safety and effectiveness of etoricoxib in paediatric<br />patients have not been established (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical studies, etoricoxib has been demonstrated not to be genotoxic. Etoricoxib was not<br />carcinogenic in mice. Rats developed hepatocellular and thyroid follicular cell adenomas at<br />&gt;2-times the daily human dose [90 mg] based on systemic exposure when dosed daily for<br />approximately two years. Hepatocellular and thyroid follicular cell adenomas observed in rats<br />are considered to be a consequence of rat-specific mechanism related to hepatic CYP enzyme<br />induction. Etoricoxib has not been shown to cause hepatic CYP3A enzyme induction in<br />humans.<br />In the rat, gastrointestinal toxicity of etoricoxib increased with dose and exposure time. In the<br />14-week toxicity study etoricoxib caused gastrointestinal ulcers at exposures greater than those<br />seen in man at the therapeutic dose. In the 53- and 106-week toxicity study, gastrointestinal<br />ulcers were also seen at exposures comparable to those seen in man at the therapeutic dose. In<br />dogs, renal and gastrointestinal abnormalities were seen at high exposures.<br />Etoricoxib was not teratogenic in reproductive toxicity studies conducted in rats at 15<br />mg/kg/day (this represents approximately 1.5 times the daily human dose [90 mg] based on<br />systemic exposure). In rabbits, a treatment related increase in cardiovascular malformations was<br />observed at exposure levels below the clinical exposure at the daily human dose (90 mg).<br />However no treatment-related external or skeletal foetal malformations were observed. In rats and<br />rabbits, there was a dose dependent increase in post implantation loss at exposures greater than<br />or equal to 1.5 times the human exposure (see sections 4.3 and 4.6).<br />Etoricoxib is excreted in the milk of lactating rats at concentrations approximately two-fold<br />those in plasma. There was a decrease in pup body weight following exposure of pups to milk<br />from dams administered etoricoxib during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core:<br />Pregelatinized maize starch<br />Microcrystalline cellulose<br />Croscarmellose sodium<br />Colloidal silicon dioxide<br />Hidroxipropilcelullose<br />Magnesium stearate<br />Tablet coating:<br />Opadry Y-1-7000<br />tablets also contain indigo carmine lake (E132) and iron oxide yellow<br />(E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br />Arxia 120 mg film-coated tablets is contained in packs of 7tablets in 1 blister pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.
Olaz-Chipi,10. Polígono Industrial Areta,
31620 Huarte-Pamplona (Navarra) – Spain
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                8 July 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>